GERMANTOWN, Md., June 16, 2017 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and
health of the planet, today announced that it has completed the
acquisition of GenVec, Inc. (NASDAQ: GNVC), a clinical-stage
biopharmaceutical company and pioneer in the development of
AdenoVerse™ gene delivery technology platform.
With the addition of GenVec's AdenoVerse™ technology and
accomplished team, Intrexon intends to create the next generation
of adenoviral (AdV) delivery with significantly higher payload
capacity that exceeds 30kb, as compared to current viral delivery
methods ranging from 4.5kb – 9kb, through a scalable manufacturing
platform utilizing helper-dependent adenovirus. This expanded
capacity will further advance the field of gene-based medicine by
enabling delivery of multiple therapeutic effectors that is not
possible with current viral delivery systems.
Additionally Intrexon's RheoSwitch Therapeutic
System® platform combined with GenVec's AdV-based
technology is projected to accelerate its ability to develop
cutting-edge gene therapies that regulate in
vivo expression of one or several therapeutic
effectors. GenVec's selection of vector origins and serotypes
as well as know-how in specifying cellular and tissue targets is
expected to expedite the design and production of vectors that
complement Intrexon's multigene programming and keen focus on
safety with limited off-target effect.
"GenVec's AdenoVerse™ platform is highly adaptable and can be
customized to develop applications for regenerative and cell
therapeutics as well as gene and antigen delivery strategies,"
commented Thomas D. Reed, Ph.D.,
Intrexon's Chief Science Officer. "The breadth of GenVec's natural
and engineered adenovector serotypes displaying valuable targeted
tissue specificity, when combined with our RheoSwitch Therapeutic
System® gene switch offer significant potential for
cutting-edge in vivo multi-gene therapies."
Douglas E. Brough, Ph.D.,
GenVec's Chief Scientific Officer stated, "We look forward to
combining our research and drug development team with Intrexon to
advance groundbreaking in vivo therapeutics. Together we
expect to develop a next-generation delivery platform capable of
increasing payload capacity far beyond that of other viral methods
for application to Intrexon's current and future health
programs."
About Intrexon Corporation
Intrexon Corporation
(NYSE: XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve
the quality of life and the health of the planet. The
Company's integrated technology suite provides its partners across
diverse markets with industrial-scale design and development of
complex biological systems delivering unprecedented control,
quality, function, and performance of living cells. We call
our synthetic biology approach Better DNA®, and we
invite you to discover more at www.dna.com or follow us on Twitter
at @Intrexon, on Facebook, and LinkedIn.
Trademarks
Intrexon, RheoSwitch Therapeutic System,
Powering the Bioindustrial Revolution with Better DNA, and Better
DNA are trademarks of Intrexon and/or its affiliates. Other names
may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information regarding Intrexon Corporation,
contact:
Investor Contact:
Christopher
Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com
Corporate Contact:
Marie
Rossi, Ph.D.
Director, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intrexon-integrates-leading-adenoviral-gene-delivery-technology-with-completion-of-genvec-acquisition-300475225.html
SOURCE Intrexon Corporation